drugset

drugset / Trial / NCT06314373

A Study for HSK39775 in Participants With Solid Tumors

NCT06314373 ↗

Phase 1/2 Recruiting 243 enrolled Xizang Haisco Pharmaceutical Co., Ltd

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Timeline

Start: 2024-03-07
Primary completion: 2028-02-01
Completion: 2028-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK39775	Unknown	—	Oral

Indications